Using various approaches for isolating and characterizing the binding receptors of GCs, as well as employing genetically modified cell and animal models, we discovered Tau as a low-affinity receptor for GCs, required for GC-stimulated osteoclastogenesis and osteoporosis. The gene discussed is MAPT; the disease is osteoporosis.